Key result
Intensive BP control cut 7-year all-cause dementia (8.85% vs 10.55%; RR 0.85).
Why the trial?
Hypertension is a leading modifiable risk factor for dementia, yet randomised evidence that sustained, intensive blood pressure control lowers dementia risk was lacking. CRHCP's long-term follow-up addressed that question.
Does a nonphysician community healthcare provider-led intensive blood pressure management program reduce cardiovascular events in adults with hypertension?
| Outcome | Intensive BP | Usual care |
|---|---|---|
| All-cause dementia at 7 years | 8.85% | 10.55% |
| Hot Line primary · adjusted RR 0.85 (95% CI 0.78–0.91; p<0.001); from the trial record, not the linked Circulation abstract | ||
| CVD composite (MI, stroke, HF hosp., CVD death) over 7 years | 2.4%/person-yr | 3.0%/person-yr |
| HR 0.76 (95% CI 0.72–0.81; p<0.0001) · primary of the Circulation CVD analysis | ||
| BP <130/80 mmHg at 7 years | 33.9% | 10.5% |
| Mean BP 138.8/80.7 vs 152.3/86.1 mmHg (difference −13.5/−5.4; p<0.0001) | ||
Safety
Intensive control increased hypotension (RR 1.58, 95% CI 1.39–1.79) and mild hypokalemia (RR 1.38, 95% CI 1.23–1.56) over 7 years; per-arm counts not reported.
Design limitations
The dementia result is not in the linked publication abstract, its denominators and ascertainment methods are not described, and 2,661 participants (7.8%) did not enter the posttrial follow-up (33,995 → 31,334).
Representation
Cluster-randomized design in rural China with trial-supplied discounted/free drugs and provider incentives may limit generalizability.
Does a nonphysician community healthcare provider-led intensive blood pressure management program reduce cardiovascular events in adults with hypertension?
Relative Risk: 0.85 (95% CI 0.78–0.91)
Absolute Event Rate: 8.85% vs 10.55%
p-value: p=<0.001
A nonphysician-led intensive blood pressure management program targeting <130/80 mm Hg provides sustained cardiovascular risk reduction over 7 years, even after the withdrawal of trial-specific financial incentives and discounted medications.
No takes yet. Share an insight, caveat, or question.
Experts read the CRHCP dementia result as landmark evidence that intensive blood pressure control prevents dementia, with several calling it practice-changing and urging broad adoption of the community-provider model.
The reaction is overwhelmingly positive: commentators describe this as the first definitive randomised evidence that lowering blood pressure reduces dementia risk, and they view the community-healthcare-provider delivery model as scalable worldwide. Some voices go further, arguing the approach could work not only in low-resource rural settings but also in high-income health systems. The live question is whether guidelines and policymakers will move to adopt non-physician-led intensive blood pressure programmes on the strength of this trial.
Multiple experts agree that the CRHCP result is definitive proof that blood pressure reduction prevents dementia and that the intervention should be adopted broadly.
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Experts have not addressed whether guideline bodies will formally endorse the non-physician community-provider model or how it would translate to high-resource health systems with different regulatory frameworks. It also remains open whether the dementia benefit extends equally across age groups and risk strata, and whether the blood pressure separation observed here can be sustained at scale without the trial's initial free medications and incentives.
Jones calls this the first definitive evidence of dementia risk reduction from a randomised controlled trial, describing it as "world-changing." He adds that the CRHCP approach might not be limited to low-resource settings and could also work in places like the US if the healthcare community embraces the model.
He states the intervention should be widely adopted and scaled up to reduce the global burden of dementia. He also notes the cardiovascular benefit was consistent between older and middle-aged individuals and between those at high and not-high cardiovascular risk.
Whelton notes that the achieved separation in blood pressure was greater than in any other major trial, including SPRINT, and calls the resulting prevention of cardiovascular disease and all-cause mortality remarkable. He argues the trial shows a simple, well-delivered intervention is very effective and questions the need for individualisation of antihypertensive therapy in most adults.
Intensive BP control cut all-cause dementia at 7 years (8.85% vs 10.55%; RR 0.85); supports scaling NPCHP-led intensive BP programs for both dementia and CVD prevention.
BACKGROUND: Hypertension is the leading risk factor for cardiovascular disease (CVD) worldwide. Implementation-based blood pressure (BP) control programs improve BP control and reduce CVD risk, but whether their benefits persist after withdrawal of trial-supported intervention components remains uncertain, especially when intensive BP control is targeted. In CRHCP (China Rural Hypertension Control Project), a nonphysician community healthcare provider (NPCHP)–led program with the intensive target of <130/80 mm Hg reduced CVD risk during the 4-year active intervention period. We extended follow-up for an additional 3 years to assess BP control and CVD outcomes over the 7-year overall period and during the 3-year posttrial period. METHODS: CRHCP was a cluster-randomized controlled trial conducted in rural China. Eligible participants were ≥40 years of age with BP ≥140/90 mm Hg or ≥130/80 mm Hg if at high CVD risk or receiving antihypertensive treatment. We randomly assigned 326 villages 1:1 to NPCHP-led intensive BP control or usual care. During the 4-year intervention, trained NPCHPs initiated and titrated antihypertensive medications using a standardized protocol under primary care physician supervision and provided coaching on home BP monitoring, lifestyle modification, and medication adherence. The program also provided discounted or free antihypertensive medications, additional training, and performance incentives. Participants in the usual care group received local standard BP management throughout. During the 3-year posttrial period from years 4 to 7, intervention participants continued care with their original NPCHPs, with physician and hypertension specialist consultation available; discounted or free medications, additional training, and performance incentives were discontinued. The primary outcome was a composite of myocardial infarction, stroke, hospitalization for heart failure, and CVD death. Treatment effects were evaluated separately over the 7-year overall and 3-year posttrial periods with prespecified subgroup analyses. RESULTS: Between May 8 and November 28, 2018, 33 995 participants were enrolled; 31 334 entered the posttrial follow-up. At the end of the 7-year overall period, BP was 138.8/80.7 mm Hg in the intervention group versus 152.3/86.1 mm Hg in the usual care group (between-group difference, −13.5/−5.4 mm Hg; P <0.0001 for both systolic and diastolic BPs); percentage of the participants with BP <130/80 mm Hg was 33.9% versus 10.5% ( P <0.0001). During the 7-year overall period, the rate of composite CVD events was 2.4% versus 3.0% per person-year in the intervention and usual care groups, respectively (hazard ratio, 0.76 [95% CI, 0.72–0.81]; P <0.0001). During the 3-year posttrial period, the corresponding rates were 3.4% versus 4.2% per person-year (hazard ratio, 0.79 [95% CI, 0.73–0.85]; P <0.0001). Posttrial effects in CVD risk reduction were generally consistent across subgroups defined by baseline age, sex, education, and antihypertensive medication use. Over the 7-year overall period, the intervention group had higher risks of hypotension (risk ratio, 1.58 [95% CI, 1.39–1.79]) and mild hypokalemia (risk ratio, 1.38 [95% CI, 1.23–1.56]; P <0.001 for both). CONCLUSIONS: Multicomponent BP management strategy with a BP target <130/80 mm Hg led by NPCHPs achieved sustained BP control and reduced CVD risk during both the 7-year overall and 3-year posttrial periods. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03527719.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Sun et al. (2026) conducted an RCT in Hypertension (n=33,995). NPCHP-led intensive BP control vs. Usual care was evaluated on All-cause dementia at 7 years (RR 0.85, 95% CI 0.78-0.91, p=<0.001). Intensive BP control cut all-cause dementia at 7 years versus usual care (8.85% vs 10.55%; adjusted RR 0.85, 95% CI 0.78-0.91; p<0.001). Composite CVD events over 7 years were lower as well (HR 0.76), but dementia is this Hot Line's primary.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: